The discovery and development of our first-in-class Hec1/Nek2 inhibitor, oral anti-cancer drug T-1101 (Tosylate), have been accepted for an oral presentation at the 19th Annual Congress of International Drug DiscoveryScience & Technology (IDDST-2023).

T-1301 Phase I clinical trial is to be initiated in Mid-December, 2021 in multiple centers in Taiwan. T-1301 is a small molecular multi-target tyrosine kinase inhibitor (TKI), exhibiting potential of multiple anti-cancer indications. The Phase I trial is to evaluate safety and tolerability of T-1301, the recommended Phase 2 dose (RP2D), and the pharmacokinetics in human, and to assess the …

Following IND approval by the US FDA in Mid-June, 2021, Taivex submitted the Phase I clinical trial application to the Taiwan FDA later on June 28 and received approval on August 20. The anticipated initiation of the Phase I trial remains by end of 2021. T-1301 Phase I trial is a multi-centered study in Taiwan. The oral solid dosage form …

T-1201 which IND application has been approved by US FDA and TFDA and the Phase I clinical trial has been initiated in June, 2021. T-1201 is a small molecular drug conjugate (SMDC), exhibiting potential of multiple anti-cancer indications. The Phase I trial is to evaluate safety and tolerability of T-1201, the recommended Phase 2 dose (RP2D), and the pharmacokinetics in …